Three separate multi-center studies were conducted by researchers at John Theurer Cancer Center at HackensackUMC, analyzing proteasome inhibitor carfilzomib which have been published in the journal Blood. Carfilzomib is a novel, highly selective proteasome inhibitor, a type of medication that blocks the actions of certain proteins (proteasomes) that cancer cells need to survive and multiply. Carfilzomib is also known by its branded name Kyprolis. On ...via Medindia Health News More READ
No comments:
Post a Comment